| Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1% |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for. |
businesswire.com |
2025-05-16 10:59:00 |
Czytaj oryginał (ang.) |
| Final Trade: RIO, FCX, X, BMY |
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. |
youtube.com |
2025-05-15 22:27:28 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know |
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-05-14 14:06:12 |
Czytaj oryginał (ang.) |
| Income Alert: 2 Bargain Blue Chips, Up To 8% Yield |
The S&P 500's dividend yield sits near a historical low, making undervalued individual stocks far more appealing. Bristol Myers Squibb offers a 5.3% yield and trades at a low PE of 6.8, with strong profitability and a robust drug pipeline. MPLX provides a 7.8% distribution yield, supported by essential midstream assets, strong cash flow, and a solid balance sheet with a low leverage ratio. |
seekingalpha.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label |
Hawaii said on Friday it entered a $700 million settlement deal with pharmaceutical firm Bristol-Myers Squibb and units of French pharmaceutical company Sanofi in a case about warning labels related to health risks from blood thinner Plavix. |
reuters.com |
2025-05-10 00:35:07 |
Czytaj oryginał (ang.) |
| Pressure is still on the pharma sector, says Mizuho's Jared Holz |
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector. |
youtube.com |
2025-05-08 23:23:04 |
Czytaj oryginał (ang.) |
| Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-05-08 14:40:54 |
Czytaj oryginał (ang.) |
| Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends |
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential. |
seekingalpha.com |
2025-05-08 13:00:00 |
Czytaj oryginał (ang.) |
| Bristol Myers to invest $40 billion in the US over 5 years, CEO says |
Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday. |
reuters.com |
2025-05-05 21:23:58 |
Czytaj oryginał (ang.) |
| First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now |
The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years. |
247wallst.com |
2025-05-01 11:15:05 |
Czytaj oryginał (ang.) |
| This High-Yield Pharma Stock Looks Like an Incredible Bargain |
When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions. |
fool.com |
2025-04-30 10:45:00 |
Czytaj oryginał (ang.) |
| Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock |
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-04-29 14:00:48 |
Czytaj oryginał (ang.) |
| BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock? |
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock. |
zacks.com |
2025-04-28 14:20:38 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That May Rocket Higher In April |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2025-04-28 11:16:34 |
Czytaj oryginał (ang.) |
| Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap |
Earnings season offers opportunities to buy undervalued blue-chip stocks like Verizon and Bristol Myers Squibb, both yielding 5-7% and trading below historical PE ratios. Verizon's growth in 5G, broadband, and prepaid services, combined with cost optimization, supports its 6.5% yield and potential for market-beating returns. Bristol Myers Squibb's focus on innovative medicines, cost savings, and a strong balance sheet underpins its 5.2% yield and long-term growth potential. |
seekingalpha.com |
2025-04-28 11:15:00 |
Czytaj oryginał (ang.) |
| 4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off |
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts. |
fool.com |
2025-04-26 22:05:00 |
Czytaj oryginał (ang.) |
| 5 Positives From Bristol-Myers Squibb's Q1 2025 Results |
Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised positively, beating estimates by 20%. BMS upgraded its 2025 guidance a bit too, reducing expected revenue shrinkage to 4.1% and raising non-GAAP EPS expectations by 2.24%. |
seekingalpha.com |
2025-04-25 14:27:06 |
Czytaj oryginał (ang.) |
| Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance |
Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth portfolio is thriving, with significant YoY increases in key drugs, offsetting declines in its legacy products. BMY's consistent dividend growth and strong profitability make it an attractive income investment, especially as the Fed reduces rates. |
seekingalpha.com |
2025-04-25 13:00:00 |
Czytaj oryginał (ang.) |
| Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results |
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Thursday. |
benzinga.com |
2025-04-24 17:11:20 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know |
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-02-26 12:05:44 |
Czytaj oryginał (ang.) |
| Got $200? 2 Healthcare Stocks to Buy and Hold Forever |
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns. |
fool.com |
2025-02-26 06:32:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review |
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (mCRC). |
benzinga.com |
2025-02-24 14:24:57 |
Czytaj oryginał (ang.) |
| Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here |
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates are shifting the risk/reward balance towards value stocks, making them more attractive compared to growth stocks. The AI revolution and liquidity improvements temporarily boosted growth stocks, but these tailwinds may not sustain long-term outperformance. |
seekingalpha.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success |
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is Breyanzi, whose sales amounted to $263 million in the fourth quarter of 2024, an increase of 160.4% year-on-year. On the other hand, Camzyos is gradually becoming the flagship of Bristol-Myers Squibb's cardiovascular franchise. |
seekingalpha.com |
2025-02-21 17:36:10 |
Czytaj oryginał (ang.) |
| BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing |
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million. |
prnewswire.com |
2025-02-20 02:49:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant. |
businesswire.com |
2025-02-19 08:59:00 |
Czytaj oryginał (ang.) |
| Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills |
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” - Barron's Weekly. In a Barron's interview, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said. |
seekingalpha.com |
2025-02-16 09:53:39 |
Czytaj oryginał (ang.) |
| New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis. |
businesswire.com |
2025-02-16 08:59:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial. |
businesswire.com |
2025-02-13 18:16:00 |
Czytaj oryginał (ang.) |
| BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? |
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind. |
zacks.com |
2025-02-11 16:56:11 |
Czytaj oryginał (ang.) |
| What's Going On With Bristol Myers Squibb Stock On Monday? |
Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma. |
benzinga.com |
2025-02-10 12:41:49 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It |
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-02-10 12:06:23 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook |
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a recent share price decline, BMY's strategic cost reductions, debt repayments, and dividend commitments highlight its long-term growth and shareholder return focus. LOE risks for key drugs like Yervoy and Eliquis and cautious 2025 guidance suggest temporary volatility, justifying a "Hold" rating at the current share price. |
seekingalpha.com |
2025-02-10 10:15:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma. |
businesswire.com |
2025-02-10 08:59:00 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down |
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focuses on developing a 'growth portfolio' and pipeline execution, with promising approvals like subcutaneous Opdivo and Cobenfy. Despite significant debt and uncertainty, Bristol-Myers is a compelling contrarian buy if pipeline execution offsets the $25B at-risk revenue from patent expirations. |
seekingalpha.com |
2025-02-07 15:00:08 |
Czytaj oryginał (ang.) |
| Weak Guidance from Bristol-Myers Could Be Creating an Opportunity |
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. |
marketbeat.com |
2025-02-07 09:27:06 |
Czytaj oryginał (ang.) |
| Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday |
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly. |
youtube.com |
2025-02-06 15:44:07 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript |
Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Chris Shibutani - Goldman Sachs Tim Anderson - Bank of America Mohit Bansal - Wells Fargo Securities Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities David Risinger - Leerink Partners Matt Phipps - William Blair Steve Scala - Cowen Kripa Devarakonda - Truist Securities Olivia Brayer - Cantor Fitzgerald James Shin - Deutsche Bank Sean McCutchen - Raymond James Alexandria Hammond - Wolfe Research Operator Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-02-06 15:41:17 |
Czytaj oryginał (ang.) |
| BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook |
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations. |
zacks.com |
2025-02-06 15:11:16 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade |
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families. |
fool.com |
2025-01-04 07:19:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors |
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session. |
zacks.com |
2025-01-03 21:12:20 |
Czytaj oryginał (ang.) |
| Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz |
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year |
youtube.com |
2025-01-03 14:06:01 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference |
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference. |
businesswire.com |
2025-01-03 08:59:00 |
Czytaj oryginał (ang.) |
| Final Trade: XLE, PANW, XHB, BMY |
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. |
youtube.com |
2025-01-02 20:17:40 |
Czytaj oryginał (ang.) |
| Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? |
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-12-31 12:16:32 |
Czytaj oryginał (ang.) |
| 2 High-Yield Dividend Stocks to Buy Early in 2025 |
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their combination of above-average dividend yields and proven business models. |
fool.com |
2024-12-31 09:45:00 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval |
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval |
seekingalpha.com |
2024-12-30 14:30:17 |
Czytaj oryginał (ang.) |
| U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2 |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications. |
businesswire.com |
2024-12-27 19:37:00 |
Czytaj oryginał (ang.) |
| US FDA approves injectable form of Bristol Myers' Opdivo |
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. |
reuters.com |
2024-12-27 13:35:39 |
Czytaj oryginał (ang.) |
| Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-26 12:40:29 |
Czytaj oryginał (ang.) |
| BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer |
The European Commission approves Bristol Myers' Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer. |
zacks.com |
2024-12-24 14:11:22 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis. |
businesswire.com |
2024-12-23 08:59:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer |
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult. |
businesswire.com |
2024-12-23 08:45:00 |
Czytaj oryginał (ang.) |
| Want Decades of Passive Income? 3 Stocks to Buy Right Now |
Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio. |
fool.com |
2024-12-21 06:24:00 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects |
BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new oncology registrational trials added in past year, as the management seeks to deliver new growth opportunities in the face of upcoming patent cliff. These developments also lend strength to BMY's Growth portfolio outperformance by +20% YoY, with the growth-to-legacy portfolio ratio increasingly skewed to the former at 48.7%. |
seekingalpha.com |
2024-12-20 16:00:00 |
Czytaj oryginał (ang.) |
| Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued |
Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has promising new drugs like Cobenfy to offset potential revenue declines. Recent quarterly results show solid revenue growth, though earnings per share have declined, and management has raised revenue guidance for the fiscal year. |
seekingalpha.com |
2024-12-20 10:00:00 |
Czytaj oryginał (ang.) |
| Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today |
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session. |
zacks.com |
2024-12-19 20:51:17 |
Czytaj oryginał (ang.) |
| 3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income |
If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio. |
fool.com |
2024-12-19 12:00:00 |
Czytaj oryginał (ang.) |
| Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer |
MIDDLETON, Wis.--(BUSINESS WIRE)-- #HealthtechInnovation--Imbed Biosciences today announced that Terry Bromley has joined as Chief Executive Officer. With over 30 years of experience in the medical device, regenerative medicine and wound and skin markets, Mr. Bromley will be instrumental in fostering the company's growth and continue Imbed Biosciences' mission to transform the future of soft tissue repair through advanced technologies focused on improving patient outcomes. “Terry brings a wealth of commercial leadersh. |
businesswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |